Year: 2020
Type: article
Abstract: Multiple sclerosis (MS) is an inflammatory disease of the CNS resulting in neurologic disability that often progresses over time. Because the prognosis varies highly among patients, prognostic markers can help guide treatment decisions. Neurofilament light (NfL) is a biomarker consisting of structural elements of neurons released in the CSF after axonal injury in various neurologic disorders.1 Nowadays, NfL can also reliably be quantified in serum by single-molecule array assays.1 This makes NfL the ideal candidate biomarker of acute and chronic axonal damage. Serum NfL increases in patients with MS during relapses2,3 and in the presence of gadolinium-enhancing lesions on MRI.3,4 Consequently, NfL has been the designated serum biomarker for MS disease activity and treatment response.
Source: Neurology
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3028268348